A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021)

NCT01535118 | Completed Results

• 1 other identifier: 7243-021
• Study Type: observational
• Target: 2,765
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study will gather information on allergic rhinoconjunctivitis from surveys completed by adults and children.

Conditions

Allergic Rhinoconjunctivitis

Keywords

Allergies; Immunotherapy

Outcome Measures

Primary Outcomes (5)

• Percentage of Participants Who Experienced Daily Symptoms Due to Allergic Rhinoconjunctivitis (ARC)

  Participants were asked about the frequency and severity of ARC symptoms when allergies were at their worst. The percentages of participants who experienced different symptoms of ARC on a daily basis when allergies were at their worst were calculated.

  Within 12 months prior to survey

• Percentage of Participants Who Experienced Work or School Absence Due to ARC in the Past 12 Months

  Participants were asked about the impact of ARC on loss of work and school time. The percentage of participants who experienced work or school absence due to ARC in the prior 12 months was calculated.

  Within 12 months prior to survey

• Percentage of Participants Who Used Medication to Treat ARC in the Past 12 Months

  Participants were asked about prescription and over-the-counter medication use for ARC. The percentages of participants who used prescription and/or over-the-counter medication to treat ARC in the past 12 months were calculated.

  Within 12 months prior to survey

• Percentage of Participants Who Received Immunotherapy to Treat ARC

  Participants who had ever received immunotherapy for ARC were asked about the type of immunotherapy - subcutaneous or sublingual - received. The percentage of participants who received immunotherapy to treat ARC was calculated.

  Within 12 months prior to survey

• Percentage of Participants Who Received Allergy Shots and Required Supplemental Prescription Allergy Medication

  Participants who received subcutaneous immunotherapy (allergy shots) were asked about prescription and over-the-counter medication use. The percentage of participants who received allergy shots to treat ARC, had not taken over-the-counter allergy medication and required supplemental prescription allergy medication for ARC was calculated.

  Within 12 months prior to survey

Secondary Outcomes (1)

• Percentage of Participants Who Received Allergy Shots and Had a Co-morbid Condition of Asthma

  Within 12 months prior to survey

Study Arms (1)

Adults and Children with Allergic Rhinoconjunctivitis (ARC)

Adults and children with ARC who complete the survey

Eligibility Criteria

• Age: 5 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults and children with ARC in the United States.

You may qualify if:

• Diagnosed with hay fever, rhinitis or nasal and/or eye allergies and display symptoms of sneezing, itching, watery eyes, nasal congestion, or other nasal or eye allergy symptoms over the past 12 months OR take any medication for their hay fever, rhinitis, nasal or eye allergies
• years of age or older
• Have a telephone

You may not qualify if:

• If less than 18 years old and there is no adult available that is knowledgeable about the participant's health

Sponsors & Collaborators

• ALK-Abelló A/S: lead

Related Publications (1)

• Blaiss MS, Dykewicz MS, Skoner DP, Smith N, Leatherman B, Craig TJ, Bielory L, Walstein N, Allen-Ramey F. Diagnosis and treatment of nasal and ocular allergies: the Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) surveys. Ann Allergy Asthma Immunol. 2014 Apr;112(4):322-8.e1. doi: 10.1016/j.anai.2014.02.006.

  PMID: 24679733 RESULT

MeSH Terms

Conditions

Hypersensitivity

Condition Hierarchy (Ancestors)

Immune System Diseases

Results Point of Contact

• Title: Senior Vice President, Global Clinical Development
• Organization: Merck Sharp & Dohme Corp.

ClinicalTrialsDisclosure@merck.com

1-800-672-6372

Publication Agreements

• PI is Sponsor Employee: Yes
• Restrictive Agreement: No

Study Design

• Study Type: observational
• Observational Model: ECOLOGIC OR COMMUNITY
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 14, 2012
• First Posted: February 17, 2012
• Study Start: January 1, 2012
• Primary Completion: May 1, 2012
• Study Completion: May 1, 2012
• Last Updated: March 3, 2017
• Results First Posted: January 27, 2014

Record last verified: 2017-01